SCHEMBL4154549

SCHEMBL4154549

CSc1ncc(C=O)c(NC2CCOCC2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MERTK Q12866 2/20 0.41
MAPK1 P28482 4/20 0.41
PDE4B Q07343 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
MEN1 O00255 1/20 0.39
GABBR2 O75899 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GABBR1 Q9UBS5 1/20 0.39
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
PIK3CA P42336 1/20 0.36
CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26090353 0.92 MERTK (0.38) MERTKMAPK1PDE4BJAK2JAK1
SCHEMBL30346284 0.92 MERTK (0.38) MERTKMAPK1PDE4BJAK2JAK1
SCHEMBL3535605 0.90 MERTK (0.48) MERTKPDE4BJAK2JAK1MEN1
SCHEMBL2553480 0.89 KMT2A (0.49) MERTKJAK2JAK1MEN1GABBR2
SCHEMBL574174 0.88 KMT2A (0.51) MERTKJAK2JAK1MEN1GABBR2
SCHEMBL31357116 0.86 MERTK (0.38) MERTKPDE4BJAK2MEN1GABBR2
SCHEMBL4712427 0.86 KMT2A (0.50) MERTKPDE4BJAK2JAK1MEN1
SCHEMBL26110421 0.86 MERTK (0.38) MERTKPDE4BJAK2MEN1GABBR2
SCHEMBL2559554 0.86 KMT2A (0.50) MERTKPDE4BJAK2JAK1MEN1
SCHEMBL22860490 0.85 MERTK (0.45) MERTKPDE4BJAK2MEN1GABBR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221998-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2025-07-10 US disclosed
EP-4504730-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 Dana-Farber Cancer Institute, Inc. (US) 2025-02-12 EP disclosed
CN-119365454-A Discovery of covalent EGFR inhibitors through cysteine 775 丹娜-法伯癌症研究院 2025-01-24 CN disclosed
WO-2023196409-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-12 WO disclosed
WO-2023196409-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-10-12 WO disclosed
US-20090221600-A1 PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (IN) 2009-09-03 US disclosed
EP-1931667-A1 PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007036791-A1 PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS RANBAXY LABORATORIES LIMITED (US) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221600-A1 PYRIDO-PYRIDIMIDINE DERIVATIVES USEFUL AS ANTIINFLAMMATORY AGENTS PNPO, TPMT, NOD1 MERTK 519/4885MAPK1 161/4885PDE4B 782/4885
US-20250221998-A1 DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 EGFR, ERBB2, ERBB3 MERTK 322/4885MAPK1 247/4885PDE4B 4362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.